John Solomon

John Solomon

Auto-generated profile, based on publicly available information

John Solomon

Patient Safety and Pharmacovigilance , Sanofi , Reading , Berkshire, UK , sanofi.com

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Health & Social Care in the Community
Verified
Journal Article
Open access
PDF file
SCSandrine Colas
Sandrine Colas
TNTiffany Nishikawa
Tiffany Nishikawa
DBDavid Bigat
David Bigat
JSJohn Solomon
John Solomon
SKSigal Kaplan
Sigal Kaplan
MKMarie-Laure Kürzinger
Marie-Laure Kürzinger
Purpose: To report UK‐specific results from a post‐authorisation safety study (PASS) that assessed the impact of additional risk minimisation measures (aRMMs), issued in Europe in 2018, regarding the use of valproate in women of childbearing potential (WCBP) and during pregnancy. Methods: The PASS was conducted among three healthcare professional (HCP) target groups (prescribing physicians, gynaecologists and pharmacists) and among WCBP treated with valproate for epilepsy, bipolar disorder or other indications. In the United Kingdom, 374 HCPs and 194 patients participated. Criteria for success were prespecified in the dimensions of awareness, knowledge and behaviour (expected answers given to ≥ 80% of questions) and overall success (≥ 90% of HCPs or ≥ 80% of patients giving expected answers in the behaviour dimension plus one of the two other dimensions). Results: Reported scores for HCPs and patients did not meet the prespecified individual dimension or overall success criteria. However, they were implementing many of the requirements of the aRMMs. Among dimensions, HCPs recorded highest scores for awareness (44%–76%). For behaviour, prescribing physicians scored highly for ensuring patients’ understanding of the annual review form (88%–97%), advising patients of the need for contraception (89%–99%) and counselling patients planning for pregnancy (67%–100%). Reported patient scores were highest in the behaviour dimension (66%), particularly for using contraception (90%) and intending to consult their physician if pregnant (95%) or planning to become pregnant (90%). Conclusion: Although prespecified criteria for success were not met, reported scores indicate that many of the requirements were being implemented to ensure appropriate use of valproate in WCBP. However, further investigation is needed into the barriers preventing adherence with certain measures of the pregnancy prevention programme.